New Study Indicates Key Differences Between Trial Enrollees and Patients Receiving Treatments

Get Permission

A new article published in the Journal of Oncology Practice evaluates differences between the treatment of patients with metastatic renal cell cancer who participated in clinical trials vs those who received the same therapy in routine clinical practice.

Nearly 40% of patients in the real-world registry would not have qualified for the clinical trials testing the therapies they ultimately received. The characteristics of the real-world patients with cancer are often not well represented in clinical trials as a result of specific eligibility criteria. Clinical research with more inclusive eligibility criteria during phase III testing and/or postmarketing studies may improve the generalizability of research findings to the broader patient population.

As rapid changes to the practice of oncology continue, it is vital to monitor and respond to practice patterns and outcomes, so oncologists can best understand treatment choices and generate clinically relevant research. In addition to higher participation, the authors note that rapid-learning health systems may additionally offer oncologists a way to readily access all available data.

To read the article, go to:  ■

© 2015. American Society of Clinical Oncology. All rights reserved.





By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.